Daytrana is a therapeutic drug owned by Noven Pharms Inc. It is primarily formulated with the active ingredient, methylphenidate. The drug first received market authorization on 6th April, 2006 and is available in film, extended release;transdermal dosage forms.
The generic version of Daytrana could potentially be released after 7th October, 2025. This is connected to the expiration of the last patent held by Noven Pharms Inc. on Daytrana.
Daytrana is widely used as a method for transdermally delivering a drug to a user in need thereof. Its main active ingredient, methylphenidate, is responsible for its therapeutic effects.
Daytrana, owned by Noven Pharms Inc., has a total of 3 patents, none of which have yet expired. The last patent is due to expire on 7th October, 2025. The Daytrana generic version may become available subsequent to this date. Below are the details of the patent: